Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma

Table 1 Clinicopathological features of CHFR promoter methylation in GC

Variable	n	Methylated	Unmethylated	Methylated rate (%)	P value
Total	20	9	11
Age (yr)
≤ 50	6	3	3	50.00	1.000
> 50	14	6	8	42.86
Gender
Female	12	5	7	41.67	1.000
Male	8	4	4	50.00
Gastric cancer
Tumor size (cm)
< 5.0	9	5	4	55.56	0.653
≥ 5.0	11	4	7	36.36
Borrman type
I + II	10	4	6	40.00	1.000
III + IV	10	5	5	50.00
Differentiation degree
Well	6	0	6	0.00	0.014
Poorly	14	9	5	64.29
Invasive depth
Within Muscle layer	5	2	3	40.00	1.000
Penetratingmuscle layer	15	7	8	46.67
Lymph node metastasis
Positive	12	6	6	50.00	0.670
Negative	8	3	5	37.50

Table 2 Clinicopathological features of CHFR mRNA and protein expression in GC

Variable	n	Relative expression density of CHFR mRNA	t	P	Relative expression density of CHFR protein	t	P
Age (yr)			1.189	0.176		0.965	0.347
≤ 50	6	0.1400 ± 0.1572			0.3300 ± 0.3809
> 50	14	0.2800 ± 0.2187			0.2064 ± 0.1989
Gender			0.608	0.551		0.648	0.525
Female	12	0.1942 ± 0.2179			0.2125 ± 0.2618
Male	8	0.2537 ± 0.2094			0.2913 ± 0.2734
Gastric cancer
Tumor size (cm)			0.872	0.395		1.346	0.195
< 5.0	9	0.1722 ± 0.1780			0.3289 ± 0.3360
≥ 5.0	11	0.2555 ± 0.2364			0.1736 ± 0.1678
Borrman type			0.797	0.436		0.208	0.838
I + II	10	0.2560 ± 0.2312			0.2310 ± 0.2772
III + IV	10	0.1800 ± 0.1934			0.2560 ± 0.2602
Differentiation degree			3.276	0.004		5.162	0.001
Well	6	0.4106 ± 0.1574			0.5447 ± 0.2573
poorly	14	0.1364 ± 1.1772			0.1143 ± 0.1224
Invasive depth			0.296	0.907		1.243	0.230
Within muscle layer	5	0.2480 ± 0.1620			0.3678 ± 0.3346
Penetrating muscle layer	15	0.2147 ± 0.2320			0.2020 ± 0.2320
Lymph node metastasis			1.892	0.075		1.318	0.204
Positive	12	0.1500 ± 0.1839			0.1817 ± 0.2353
Negative	8	0.3200 ± 0.2190			0.3363 ± 0.2879